Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DRI Healthcare TrustDHTRF 32 3-Year Share Buyback Ratio is -13.40 as of Jun. 2026. GuruFocus rates DHTRF with a GF Score™ of 32/100 and a GF Value™ of $11.69 (Fairly Valued). The stock has 5 warning signs investors should review. Among 645 Drug Manufacturers companies, DRI Healthcare Trust ranks worse than 78.91% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. DRI Healthcare Trust's current 3-Year Share Buyback Ratio was -13.40%.
The historical rank and industry rank for DRI Healthcare Trust's 3-Year Share Buyback Ratio or its related term are showing as below:
DHTRF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -13.4 Med: -13.15 Max: -12.9
Current: -13.4
During the past 6 years, DRI Healthcare Trust's highest 3-Year Share Buyback Ratio was -12.90%. The lowest was -13.40%. And the median was -13.15%.
DHTRF's 3-Year Share Buyback Ratio is ranked worse than 78.91% of 645
companies
in the Drug Manufacturers industry
Industry Median: -2.1
vs DHTRF: -13.40
DRI Healthcare Trust (OTCPK:DHTRF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
DRI Healthcare Trust 3-Year Share Buyback Ratio Related Terms
DHTRF vs ZTS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DRI Healthcare Trust 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where DRI Healthcare Trust's 3-Year Share Buyback Ratio falls into.
DRI Healthcare Trust 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -13.40 mean?
DRI Healthcare Trust (DHTRF) has a 3-Year Share Buyback Ratio of -13.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for DRI Healthcare Trust and its competitors. According to the industry distribution chart, DRI Healthcare Trust ranks #509 out of 645 companies in the Drug Manufacturers industry, placing it in the top 78.9%.
Is DRI Healthcare Trust's 3-Year Share Buyback Ratio too high?
DRI Healthcare Trust's current 3-Year Share Buyback Ratio is -13.40. Based on the distribution chart, DRI Healthcare Trust ranks #509 out of 645 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, DRI Healthcare Trust has a GF Score™ of 32/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's 3-Year Share Buyback Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #509 out of 645 companies for 3-Year Share Buyback Ratio. This places DRI Healthcare Trust in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for DRI Healthcare Trust and its competitors. DRI Healthcare Trust's current 3-Year Share Buyback Ratio is -13.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $11.69, compared to a current price of $12.18 — trading 4.2% above its estimated fair value. The current 3-Year Share Buyback Ratio is -13.40. DRI Healthcare Trust's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current 3-Year Share Buyback Ratio is -13.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?
Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be overvalued.
The current stock price of $12.18 is trading 4.2% above its estimated GF Value™ of $11.69.
GuruFocus considers DRI Healthcare Trust to be Fairly Valued.
Key valuation signals for DHTRF:
3-Year Share Buyback Ratio: -13.40
GF Value™: $11.69 vs. price of $12.18 (4.2% above fair value)
No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
32GF Score
Get the complete analysis for DHTRF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHTRF has been successfully added to your 
